DHA supplementation improves cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial
DHA supplementation improves cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial
复制标题
DHA 补充剂通过增强 Aβ 介导的自噬改善患有轻度认知障碍的中国老年人的认知功能:一项随机安慰剂对照试验
DOI:
10.1136/jnnp-2017-316176
复制
发表时间:
2017-11
期刊:
影响因子:
--
通讯作者:
Fei Ma
中科院分区:
文献类型:
--
作者:
YanPing Zhang;Yinyin Lou;Jing Hu;Rujuan Miao;Fei Ma
BACKGROUND:.Higher docosahexaenoic acid (DHA) intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in people with mild cognitive impairment (MCI) have not been fully examined..OBJECTIVE:.Our study aimed to assess the effect of a 24-month DHA supplementation on cognitive function and amyloid beta (Aβ)-mediated autophagy in elderly subjects with MCI..METHODS:.This was a randomised, double-blind, placebo-controlled trial in Tianjin, China. A total of 240 individuals with MCI were identified and randomly divided into intervention (DHA 2 g/day, n=120) and control (corn oil as placebo, n=120) groups. Cognitive function and blood Aβ-related biomarkers were measured at baseline, 6, 12, 18 and 24 months. Data were analysed using generalised estimating equation..RESULTS:.A total of 217 participants (DHA: 109, placebo: 108) completed the trial. During the follow-up, scores of full-scale IQ, verbal IQ and subdomains of information and digit span were significantly higher in the intervention group than the convention group (p<0.05). In the intervention group, blood Aβ-42 level and expression of Aβ protein precursor mRNA were decreased (p<0.05), while Beclin-1 and LC3-II levels and expression of LC3-II mRNA were increased (p<0.05)..CONCLUSION:.Daily oral DHA supplementation (2 g/day) for 24 months may improve cognitive function and change blood biomarker-related Aβ-mediated autophagy in people with MCI. Larger longer-term confirmatory studies are warranted..TRIAL REGISTRATION NUMBER:.ChiCTR-IOR-15006058.
登录
查看更多内容
影响因子:
3.7
作者:
Jaeger PA;Pickford F;Sun CH;Lucin KM;Masliah E;Wyss-Coray T
通讯作者:
Wyss-Coray T
DOI:
10.3233/jad-160439
发表时间:
2016-11
期刊:
Journal of Alzheimer's disease : JAD
影响因子:
--
作者:
Yan-ping Zhang;Rujuan Miao;Qing Li;Tianfeng Wu;F. Ma
通讯作者:
Yan-ping Zhang;Rujuan Miao;Qing Li;Tianfeng Wu;F. Ma
DOI:
10.1017/9781108587921.004
发表时间:
2008-11
期刊:
Language in Dementia
影响因子:
--
作者:
Li Qiang
通讯作者:
Li Qiang
影响因子:
2.9
作者:
Qinghua Yao;T. Fu;Lu Wang;Yuebiao Lai;Yuqi Wang;Chao Xu;Lulu Huang;Yong Guo
通讯作者:
Qinghua Yao;T. Fu;Lu Wang;Yuebiao Lai;Yuqi Wang;Chao Xu;Lulu Huang;Yong Guo
影响因子:
3.3
作者:
Jung, Chang Hwa;Jun, Chang Bong;Kim, Do-Hyung
通讯作者:
Kim, Do-Hyung